| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Ann Thorac Surg 2002;73:843-848
© 2002 The Society of Thoracic Surgeons
a Department of Cardiovascular Surgery, Groupe Hospitalier Bichat-Claude Bernard, Paris, France
b Department of Anesthesiology, Groupe Hospitalier Bichat-Claude Bernard, Paris, France
c Department of Biochemistry, Groupe Hôspitalier Bichat-Claude Bernard, Paris, France
d National Cardiovascular Center, Fujishirodai Suita, Osaka, Japan
Accepted for publication November 1, 2001.
* Address reprint requests to Dr Menasché, Service de Chirurgie, Cardiovasculaire B, Groupe Hôspitalier Bichat-Claude Bernard, 46, rue Henri Huchard, 75877 Paris Cedex 18, France
e-mail: ccv-bloc.sec3{at}bch.ap-hop-paris.fr
Background. Activation of the kinase cascade (protein kinase C (PKC), tyrosine kinase (TK), and mitogen-activated protein kinase (MAPK) is a key feature of the transduction pathway, elicited by preconditioning signals and mediating their cardioprotective effects. We assessed whether such an activation occurred during cardiac operations and could thus represent a target for cardioprotective strategies.
Methods. A total of 20 patients undergoing coronary artery bypass grafting surgery were studied. During the first 10 minutes of cardiopulmonary bypass (CPB), 10 were treated with sevoflurane (2.5 minimum alveolar concentration), an inhalational anesthetic that mimics preconditioning through a similar activation of the kinase cascade. Ten case-matched patients undergoing 10 minutes of sevoflurane-free CPB served as controls. Right atrial biopsies were taken before and 10 minutes after CPB and were then processed for the measurement of PKC, TK, and p38 MAPK activities by enzyme assay techniques. Troponin I was also monitored over the first 2 postoperative days.
Results. Compared with pre-CPB values, PKC and p38 MAPK activities (in nanomoles per milligram of protein per minute and arbitrary units, respectively) increased significantly and to the same extent in both groups: PKC, from 20.7 ± 0.7 to 29.9 ± 3.9 in controls (p = 0.037) and from 18.4 ± 1.1 to 23.9 ± 1.8 in sevoflurane (p = 0.016); p38 MAPK, from 88.6 ± 8.5 to 312.9 ± 66.2 in controls (p = 0.005) and from 114.6 ± 14.7 to 213.4 ± 51.8 in sevoflurane (p = 0.045). Conversely, sevoflurane triggered a significant increase in TK activity (from 68.5 ± 1.4 to 83.7 ± 2.9 picomoles per milligram of protein per minute p = 0.0015) which did not occur in controls (from 67.5 ± 1.9 to 76.8 ± 4.2 picomoles per milligram of protein per minute, p = 0.09). Likewise, the peak postoperative value of troponin I was not different between controls and sevoflurane-treated patients (3.4 ± 0.6 vs 2.4 ± 0.4, p = 0.21).
Conclusions. Cardiopulmonary bypass triggers an activation of the kinase cascade that is mechanistically linked to opening of potassium channels. The direct opening of these channels by the anesthetic sevoflurane does not increase kinase activation further, nor does it improve markers of cell necrosis, thus suggesting that pharmacologically targeting potassium channels may overlap the preconditioning-like effects of CPB alone.
This article has been cited by other articles:
|
|
 |
|
  J. Frassdorf, S. De Hert, and W. Schlack Anaesthesia and myocardial ischaemia/reperfusion injury Br. J. Anaesth., July 1, 2009; 103(1): 89 - 98. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Frassdorf, A. Borowski, D. Ebel, P. Feindt, M. Hermes, T. Meemann, R. Weber, J. Mullenheim, N. C. Weber, B. Preckel, et al. Impact of preconditioning protocol on anesthetic-induced cardioprotection in patients having coronary artery bypass surgery. J. Thorac. Cardiovasc. Surg., June 1, 2009; 137(6): 1436 - 1442.e2. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Lorsomradee, S. Cromheecke, S. Lorsomradee, and S. G De Hert Cardioprotection with Volatile Anesthetics in Cardiac Surgery Asian Cardiovasc Thorac Ann, June 1, 2008; 16(3): 256 - 264. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Naydenova, J. B. Rose, and I. R. Coe Inosine and equilibrative nucleoside transporter 2 contribute to hypoxic preconditioning in the murine cardiomyocyte HL-1 cell line Am J Physiol Heart Circ Physiol, June 1, 2008; 294(6): H2687 - H2692. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Piriou, J. Mantz, G. Goldfarb, M. Kitakaze, P. Chiari, S. Paquin, C. Cornu, J.-B. Lecharny, P. Aussage, E. Vicaut, et al. Sevoflurane preconditioning at 1 MAC only provides limited protection in patients undergoing coronary artery bypass surgery: a randomized bi-centre trial Br. J. Anaesth., November 1, 2007; 99(5): 624 - 631. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Symons and P. S. Myles Myocardial protection with volatile anaesthetic agents during coronary artery bypass surgery: a meta-analysis Br. J. Anaesth., August 1, 2006; 97(2): 127 - 136. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. G. De Hert Volatile Anesthetics and Cardiac Function Seminars in Cardiothoracic and Vascular Anesthesia, March 1, 2006; 10(1): 33 - 42. [Abstract] [PDF]
|
|
|
|
 |
|
 S. G. De Hert, F. Turani, S. Mathur, and D. F. Stowe Cardioprotection with Volatile Anesthetics: Mechanisms and Clinical Implications Anesth. Analg., June 1, 2005; 100(6): 1584 - 1593. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Chaudary, Z. Naydenova, I. Shuralyova, and I. R. Coe The Adenosine Transporter, mENT1, Is a Target for Adenosine Receptor Signaling and Protein Kinase C{epsilon} in Hypoxic and Pharmacological Preconditioning in the Mouse Cardiomyocyte Cell Line, HL-1 J. Pharmacol. Exp. Ther., September 1, 2004; 310(3): 1190 - 1198. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Shuralyova, P. Tajmir, P. J. Bilan, G. Sweeney, and I. R. Coe Inhibition of glucose uptake in murine cardiomyocyte cell line HL-1 by cardioprotective drugs dilazep and dipyridamole Am J Physiol Heart Circ Physiol, February 1, 2004; 286(2): H627 - H632. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Zaugg, E. Lucchinetti, C. Garcia, T. Pasch, D. R. Spahn, and M. C. Schaub Anaesthetics and cardiac preconditioning. Part II. Clinical implications Br. J. Anaesth., October 1, 2003; 91(4): 566 - 576. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Vaage and G. Valen Preconditioning and cardiac surgery Ann. Thorac. Surg., February 1, 2003; 75(2): S709 - 714. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. G. Kevin, M. M. Sayin, O. Ozatamer, and N. U:nal Propofol and myocardial lipid peroxidation Br. J. Anaesth., February 1, 2003; 90(2): 253 - 254. [Full Text] [PDF]
|
|
|
|
|
|
U. Sunderdiek, S. Schmitz-Spanke, B. Korbmacher, E. Gams, and J. D. Schipke Preconditioning: myocardial function and energetics during coronary hypoperfusion and reperfusion Ann. Thorac. Surg., December 1, 2002; 74(6): 2147 - 2155. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
